AR044650A1 - Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa. - Google Patents
Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa.Info
- Publication number
- AR044650A1 AR044650A1 ARP040101983A ARP040101983A AR044650A1 AR 044650 A1 AR044650 A1 AR 044650A1 AR P040101983 A ARP040101983 A AR P040101983A AR P040101983 A ARP040101983 A AR P040101983A AR 044650 A1 AR044650 A1 AR 044650A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- aryl
- therapy
- hydrogen
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000003270 steroid hormone Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Abstract
Derivados de tiofenpirimidinona y su uso en terapia especialmente para uso en el tratamiento y/o prevención de una enfermedad o desorden dependiente de una hormona esteroide, tal como enfermedades o desórdenes dependientes de la hormona esteroide que requiere la inhibición de enzimas 17beta-hidroxiesteroide-dehidrogenasas. Reivindicación 3: Un compuesto de la fórmula (1), en la cual: X representa S, SO o SO2; R1 y R2 están seleccionados individualmente del grupo que comprende alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, cicloheteroalquilo, cicloheteroalquilo sustituido, aril-alquilo, aril-alquilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, cicloheteteroalquil-alquilo, cicloheteroalquil-alquilo sustituido; o R2 puede estar seleccionado independientemente entre acilo, carboxilo o amido, mientras R1 y R2 no pueden representar simultáneamente alquilo no sustituido, y R2 debe ser distinto de metilo si todos los sustituyentes R3, R5 y R6 simultáneamente representan hidrógeno y R4 representa hidrógeno o metilo; R3 y R4 están individualmente seleccionados del grupo que comprende hidrógeno, oxo, halógeno o dihalógeno, acilo, alquilo, alquilo sustituido, hidroxilo, carboxilo, amido, amino, nitrilo, tio, alcoxi, aciloxi, ariloxi, alquiltio y ariltio; R5 representa hidrógeno; R6 representa hidrógeno o halógeno, y la cadena de hidrocarburos -C(R3)-C(R4)-C(R5)-C(R6)- del ciclo de seis miembros es saturada o contiene una o dos dobles ligaduras entre los átomos de carbono; el ciclo de seis miembros que comprende la cadena de hidrocarburos -C(R3)-C(R4)-C(R5)-C(R6)- debe ser un ciclo aromático si todos los sustituyentes R3, R4, R5 y R6 simultáneamente representan hidrógeno, para uso en terapia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47704703P | 2003-06-10 | 2003-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044650A1 true AR044650A1 (es) | 2005-09-21 |
Family
ID=34421462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101983A AR044650A1 (es) | 2003-06-10 | 2004-06-08 | Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa. |
Country Status (24)
Country | Link |
---|---|
US (1) | US7465739B2 (es) |
EP (1) | EP1635839B1 (es) |
JP (1) | JP4605800B2 (es) |
KR (1) | KR20060054189A (es) |
CN (1) | CN1791412A (es) |
AR (1) | AR044650A1 (es) |
AT (1) | ATE479437T1 (es) |
AU (1) | AU2004277311B8 (es) |
BR (1) | BRPI0411295A (es) |
CA (1) | CA2527617A1 (es) |
DE (1) | DE602004028934D1 (es) |
DK (1) | DK1635839T3 (es) |
ES (2) | ES2352552T3 (es) |
IL (1) | IL172316A0 (es) |
MX (1) | MXPA05012745A (es) |
NO (1) | NO20060123L (es) |
PL (1) | PL1635839T3 (es) |
PT (1) | PT1635839E (es) |
RU (1) | RU2412190C2 (es) |
SA (1) | SA04250159B1 (es) |
SI (1) | SI1635839T1 (es) |
TW (1) | TWI349551B (es) |
WO (1) | WO2005032527A2 (es) |
ZA (1) | ZA200508296B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
US20070232628A1 (en) * | 2004-05-06 | 2007-10-04 | Luengo Juan I | Calcilytic Compounds |
WO2006044826A2 (en) * | 2004-10-20 | 2006-04-27 | Compass Pharmaceuticals Llc | Thiophens and their use as anti-tumor agents |
BRPI0419229A (pt) * | 2004-12-13 | 2007-12-18 | Solvay Pharm Gmbh | derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica |
FR2904000A1 (fr) * | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee |
FR2904318B1 (fr) * | 2006-07-27 | 2011-02-25 | Scras | Derives de pyrimidinone et leur utilisation comme medicament |
US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
WO2009001214A2 (en) * | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
DE102007040243A1 (de) | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
CA2772760A1 (en) * | 2008-12-23 | 2010-07-01 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
WO2012025638A1 (en) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
WO2012119605A1 (en) * | 2011-03-10 | 2012-09-13 | Akar Yahya Ahmed Abdellhafeez Salem | New disperse dye with potent anticancer activity |
TW201520219A (zh) * | 2013-03-12 | 2015-06-01 | Lilly Co Eli | 咪唑並吡啶化合物 |
US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
KR20160042873A (ko) | 2013-06-25 | 2016-04-20 | 포렌도 파마 리미티드 | 17.베타.-하이드록시스테로이드 탈수소효소의 억제제로서 치료적 활성 17-질소 치환된 에스트라트리엔티아졸 유도체 |
US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
US9850272B2 (en) | 2013-06-25 | 2017-12-26 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 |
EP3089969A2 (en) | 2014-01-03 | 2016-11-09 | Elexopharm GmbH | Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2 |
WO2015114663A1 (en) | 2014-01-30 | 2015-08-06 | Council Of Scientific & Industrial Research | Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties |
GB201419102D0 (en) * | 2014-10-27 | 2014-12-10 | Imp Innovations Ltd | Novel compounds |
JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | 17β‐HSD1抑制剤のプロドラッグ |
CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
US20180312493A1 (en) * | 2015-11-04 | 2018-11-01 | Simon Fraser University | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor |
CN110945007B (zh) | 2017-06-08 | 2022-11-18 | 佛恩多制药有限公司 | 用于抑制17β-羟基类固醇脱氢酶的15β-[3-丙酰氨基]-取代的雌-1,3,5(10)-三烯-17-酮化合物及其17-肟 |
CN109503572B (zh) * | 2017-09-15 | 2021-10-08 | 上海交通大学 | 一种合成吲哚喹啉类化合物的方法 |
CN113412269A (zh) | 2018-12-05 | 2021-09-17 | 佛恩多制药有限公司 | 作为17-hsd1抑制剂的在位置16(17)具有缩合的吡唑环的雌甾-1,3,5(10)-三烯化合物 |
WO2023212019A1 (en) * | 2022-04-28 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4742271B1 (es) * | 1968-06-20 | 1972-10-25 | ||
US3775027A (en) | 1971-10-01 | 1973-11-27 | Gray Manuf Co Inc | Two-speed pump |
JPS62132884A (ja) | 1985-12-05 | 1987-06-16 | Mitsubishi Chem Ind Ltd | 2−ベンジルチエノ〔2,3−d〕ピリミジン−4(3H)−オン誘導体 |
US5124331A (en) | 1988-03-02 | 1992-06-23 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno[2,3-d]pyrimidine compounds and their pharmaceutical use |
US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
JP3783810B2 (ja) | 1997-01-14 | 2006-06-07 | 第一製薬株式会社 | 新規ベンゾフラノン誘導体及びその製造方法 |
JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
AU9001698A (en) | 1997-09-11 | 1999-03-29 | Snow Brand Milk Products Co., Ltd. | Remedies for hormone-dependent diseases |
JP2002506077A (ja) | 1998-03-11 | 2002-02-26 | アンドルシェルシュ・インコーポレイテッド | タイプ5およびタイプ317β−ヒドロキシステロイドデヒドロゲナーゼのインヒビターおよびその使用法 |
EP1102753B1 (en) | 1998-08-07 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Pyrazoles as estrogen receptor modulators |
GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
EP1326829A2 (en) | 2000-09-29 | 2003-07-16 | Bayer Pharmaceuticals Corporation | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors |
WO2003017974A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
MY141661A (en) | 2001-09-06 | 2010-05-31 | Schering Corp | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
-
2004
- 2004-06-07 US US10/861,907 patent/US7465739B2/en not_active Expired - Fee Related
- 2004-06-08 AR ARP040101983A patent/AR044650A1/es not_active Application Discontinuation
- 2004-06-08 TW TW093116411A patent/TWI349551B/zh not_active IP Right Cessation
- 2004-06-09 AU AU2004277311A patent/AU2004277311B8/en not_active Ceased
- 2004-06-09 MX MXPA05012745A patent/MXPA05012745A/es active IP Right Grant
- 2004-06-09 DE DE602004028934T patent/DE602004028934D1/de active Active
- 2004-06-09 EP EP04803089A patent/EP1635839B1/en active Active
- 2004-06-09 DK DK04803089.4T patent/DK1635839T3/da active
- 2004-06-09 PL PL04803089T patent/PL1635839T3/pl unknown
- 2004-06-09 WO PCT/EP2004/006230 patent/WO2005032527A2/en active Search and Examination
- 2004-06-09 ZA ZA200508296A patent/ZA200508296B/xx unknown
- 2004-06-09 CN CNA200480013515XA patent/CN1791412A/zh active Pending
- 2004-06-09 CA CA002527617A patent/CA2527617A1/en not_active Abandoned
- 2004-06-09 RU RU2006100033/04A patent/RU2412190C2/ru not_active IP Right Cessation
- 2004-06-09 JP JP2006515869A patent/JP4605800B2/ja not_active Expired - Fee Related
- 2004-06-09 AT AT04803089T patent/ATE479437T1/de active
- 2004-06-09 PT PT04803089T patent/PT1635839E/pt unknown
- 2004-06-09 KR KR1020057022958A patent/KR20060054189A/ko active IP Right Grant
- 2004-06-09 BR BRPI0411295-4A patent/BRPI0411295A/pt not_active IP Right Cessation
- 2004-06-09 SI SI200431535T patent/SI1635839T1/sl unknown
- 2004-06-09 ES ES04803089T patent/ES2352552T3/es active Active
- 2004-06-12 SA SA4250159A patent/SA04250159B1/ar unknown
- 2004-11-03 ES ES04805369T patent/ES2352554T3/es active Active
-
2005
- 2005-12-01 IL IL172316A patent/IL172316A0/en unknown
-
2006
- 2006-01-09 NO NO20060123A patent/NO20060123L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2412190C2 (ru) | 2011-02-20 |
ATE479437T1 (de) | 2010-09-15 |
CN1791412A (zh) | 2006-06-21 |
MXPA05012745A (es) | 2006-05-17 |
TWI349551B (en) | 2011-10-01 |
IL172316A0 (en) | 2011-08-01 |
KR20060054189A (ko) | 2006-05-22 |
DE602004028934D1 (de) | 2010-10-14 |
BRPI0411295A (pt) | 2006-08-01 |
JP4605800B2 (ja) | 2011-01-05 |
WO2005032527A2 (en) | 2005-04-14 |
ES2352554T3 (es) | 2011-02-21 |
DK1635839T3 (da) | 2011-01-03 |
CA2527617A1 (en) | 2005-04-14 |
EP1635839A2 (en) | 2006-03-22 |
WO2005032527A3 (en) | 2005-08-04 |
EP1635839B1 (en) | 2010-09-01 |
US20050038053A1 (en) | 2005-02-17 |
RU2006100033A (ru) | 2007-07-20 |
AU2004277311A1 (en) | 2005-04-14 |
WO2005032527B1 (en) | 2005-09-22 |
SI1635839T1 (sl) | 2010-12-31 |
PT1635839E (pt) | 2010-10-12 |
AU2004277311B8 (en) | 2010-05-27 |
NO20060123L (no) | 2006-03-09 |
AU2004277311B2 (en) | 2010-04-29 |
JP2006527226A (ja) | 2006-11-30 |
TW200509937A (en) | 2005-03-16 |
PL1635839T3 (pl) | 2011-02-28 |
ZA200508296B (en) | 2007-01-31 |
ES2352552T3 (es) | 2011-02-21 |
US7465739B2 (en) | 2008-12-16 |
SA04250159B1 (ar) | 2008-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044650A1 (es) | Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa. | |
NO20021358D0 (no) | Alkylendiamin-substituerte heterocykler | |
CO5690585A2 (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
ES2192081T3 (es) | Derivados de purina antivirales. | |
UY28121A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos | |
CO5570660A2 (es) | Indazolilpirrolotriazinas c-6 modificadas | |
CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
GT200100183A (es) | Derivados de quinolina y quinazolina. | |
ATE277929T1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
HN2002000317A (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
EA200800924A1 (ru) | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера | |
AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
ATE260275T1 (de) | Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one | |
AR039385A1 (es) | Derivados de tioxantina como inhibidores de la mieloperoxidasa | |
CO5611155A2 (es) | Uso de derivado de indolopirrolocarbazol y otro agente anticanceroso en combinacion | |
EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
AR024364A1 (es) | Una composicion cosmetica para el adelgazamiento a base l-arginina, de un analogo de l-arginina, o de uno de sus derivados, que se administra por viatopica | |
CO5700773A2 (es) | Derivados de bencimidazol | |
PL1601646T3 (pl) | Analogi 2-podstawionej witaminy D i ich zastosowania terapeutyczne | |
AR029214A1 (es) | Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza | |
CO5660290A2 (es) | 6-(1,1-difluoroalquil)-4-aminopicolinatos y su uso como herbicidas | |
NI200700063A (es) | Hexadecasacáridos biotinilados, su preparación y su utilización. | |
CO5640109A2 (es) | Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen | |
CO5070654A1 (es) | Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden | |
AR010098A1 (es) | COMPOSICION Y PROCEDIMIENTO PARA LA DEFORMACION PERMANENTE DEL CABELLO, Y PROCEDIMIENTO DE PREPARACIoN DE DICHA COMPOSICION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |